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Abstract
Background: Co-infection with loiasis remains a potential problem in control programs targeting filarial infections.
The effects of many anti-parasitic drugs often administered to Loa loa infected people are not well documented.
This study compared the in vitro activity of several of these drugs on the viability of L. loa microfilariae (mf).
Methods: Human strain L. loa mf were isolated from baboon blood using iso-osmotic Percoll gradient, and
cultured in RPMI 1640/10% FBS with antimalarial drugs (mefloquine, amodiaquine, artesunate, chloroquine and
quinine), anthelmintics (ivermectin, praziquantel, flubendazole and its reduced and hydrolyzed metabolites),
two potential trypanocidal agents (fexinidazole and Scynexis-7158) and the anticancer drug imatinib. The drug
concentrations used varied between 0.156 μg/ml and 10 μg/ml. Mf motility (CR50 = 50% immotility) and a
metabolic viability assay (MTT) were used to assess the effects of these drugs on the parasites.
Results: Mf in control cultures showed only a slight reduction in motility after 5 days of culture. Active
inhibition of Loa loa motility was seen with mefloquine and amodiaquine (CR50 values of 3.87 and 4.05 μg/
ml, respectively), immobilizing > 90% mf within the first 24 hours: mefloquine killed the mf after 24 hours of
culture at concentrations ≥ 5 μg/ml. SCYX-7158 also induced a concentration-dependent reduction in mf motility, with
> 50% reduction in mf motility seen after 5 days at 10 μg/ml. The anticancer drug imatinib reduced mf motility at 10
μg/ml from the first day of incubation to 55% by day 5, and the reduction in motility was concentration-dependent.
Praziquantel and fexinidazole were inactive, and FLBZ and its metabolites, as well as ivermectin at concentrations > 5
μg/ml, had very minimal effects on mf motility over the first 4 days of culture.
Conclusions: The considerable action of the anti-malarial drugs mefloquine and amodiaquine on Loa mf in vitro
highlights the possibility of repurposing the existing anti-infectious agents for the development of drugs against loiasis.
The heterogeneity in the activity of anti-parasitic agents on Loa loa mf supports the need for further investigation
using animal models of loiasis.
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Background
Loiasis, a neglected tropical disease also known as African
eye worm, is caused by the nematode Loa loa, transmitted
through the bite of deer flies (Chrysops spp.). Loiasis is
thought to cause relatively little pathology except for local-
ized mild to moderate pruritus and oedema, and distress
due to the occasional sub-conjunctival migration of the
adult worm. Although the disease is endemic in Central
and West Africa [1], 101 cases were reported outside
Africa in the past 25 years (1986–2011), of which 61 (60.
4%) were in Europe and 31 (30.7%) in the USA [2]; how-
ever, all these patients had spent time in an African
endemic area.
Although relatively asymptomatic when untreated, L.
loa-infected people, when administered the anti-parasitic
agents commonly used for other filarial infections such as
onchocerciasis and lymphatic filariasis, may experience se-
vere adverse effects, especially in people carrying very high
loads of circulating L. loa mf (> 8000 mf/ml) treated with
diethylcarbamazine or ivermectin [3–5]. This post-
treatment phenomenon has been an impediment to
programmes administering ivermectin to eliminate oncho-
cerciasis and lymphatic filariasis, both of which can co-exist
with loiasis [4, 5]. Fatal complications involving encephal-
opathy have been documented during the treatment of lo-
iasis patients [3, 6, 7]. Further, the cross-reactivity of the
Immuno-chromatographic card (ICT) with loiasis [8, 9]
has impaired the mapping of lymphatic filariasis in the
rainforest block of central Africa, where loiasis is endemic.
No registered safe drug is available for the control of lo-
iasis and no vaccine is available for loiasis or other filarial
infections, despite the considerable efforts made to under-
stand the mechanisms and major effectors of the immune
response induced by the parasite in the host [10, 11].
Pending the development of such a vaccine, the develop-
ment of a drug that can safely clear the infection would be
highly valuable for control and elimination programmes.
In the search for a safe drug for use in loiasis regions,
there is a need of an in vitro system to study the effects
of candidate drugs on the parasite viability. Although
there has been considerable success in developing pro-
tocols to maintain these parasites in primates [7, 12,
13], culture systems more amenable for higher-
throughput drug testing remain unavailable. Baboons,
along with mandrills, are important models for the
study of L. loa since they, like humans, are susceptible
to infection and develop prolonged microfilaraemia
without developing clinical disease [7, 13]. Despite the
success of maintaining L. loa parasites in baboons, this
model is practically inappropriate for in vivo drug
screening purposes at large scales; the numbers re-
quired and cost of animal maintenance, along with eth-
ical and environmental constraints, prevent the routine
use of these protected animals for research.
The development of an in vitro system for drug testing
against this parasite has been impeded by the unavailability
of the parasites in most laboratory settings, even though
blood from infected humans has been used in prior
screening of plant extracts [14]. Nevertheless, this source
of parasites is ethically inappropriate. However, it has been
shown that baboons inoculated with third-stage larvae of a
human strain of L. loa developed patent infections after
135 to 148 days; in each animal which became patent,
microfilaremia rose rapidly to high levels, followed by a
suppression of microfilaremia during the 4th month of pa-
tency. After splenectomy, microfilariae reappeared in the
peripheral blood in large numbers [13]. Thus, splenecto-
mised baboons are a good animal reservoir of L. loa mf. In
this study, this source of parasite material was used to in-
vestigate the susceptibility of mf to L3 antiparasitic drugs.
The study described here addresses the in vitro activity
of antiparasitic drugs on L. loa mf in culture. Ivermectin,
an obvious control for this study, is the drug of choice
for the treatment of onchocerciasis. This semi-synthetic
macrolide is effective in vivo against mf (but not adult
worms) of L. loa. It shows little in vitro activity against
mf [15], and this is thought to be related to the require-
ment of the host immune system to mediate mf killing
by ivermectin in vivo [16]. The anticancer imatinib
(Gleevec; GLV) was used because it was recently added
to the list of filaricidal drugs [17] and its microfilaricidal
property was reported against Brugia [18]. The benz-
imidazole flubendazole (FLBZ) has been suggested as a
candidate macrofilaricide for onchocerciasis [19], and
has been extensively investigated in a range of animal
models since its discovery over 40 years ago. The benz-
imidazoles are broad spectrum anthelmintics that bind
preferentially to parasite β-tubulin leading to the disrup-
tion of microtubules and, ultimately, to the death of the
parasite. FLBZ exhibits macrofilaricidal activity against
Brugia pahangi [20, 21], Breinlia booliati [22], and, as a
pro-drug of FLBZ (UMF-078), on Onchocerca ochengi
[23]. In addition, several studies in other filarial species
have indicated that FLBZ lacks or has only very little ac-
tivity against mf stages. For example, it is ineffective
against B. pahangi mf [21], and shows very low activity
compared to ivermectin against mf in a mouse model of
Onchocerca lienalis [24]. It was recently shown to inhibit
the development of B. malayi mf to L3 in Aedes aegypti,
while it did not affect the viability of L. loa and B.
malayi mf at 10 μM after 72 h exposure in vitro [25].
Praziquantel and the antimalarial drugs mefloquine,
artesunate, chloroquine and amodiaquine were tested as
they exhibit anthelmintic activity against Schistosoma
species [26–30]. Fexinidazole and Scynexis-7158 are new
clinical candidates currently under development against
sleeping sickness. Since the endemicity of human
African trypanosomiasis (HAT) overlaps with that of
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loiasis in some area of sub-Saharan Africa [1, 31], there
is a need to predict the effect of these drugs on the via-
bility of L. loa mf. This will help to prevent fatal compli-
cations such as those that have been observed post-mass
treatment of onchocerciasis with ivermectin in loiasis
co-endemic areas. These two new oral candidates were
suggested by the Drug for Neglected Disease initiative
(DNDi) and partners for clinical trial studies.
Fexinidazole (5-nitro-imidazole), was successfully evalu-
ated in Phase I between 2009 and 2012 and its potential
as an oral, safe and well-tolerated drug was demon-
strated [32, 33]. Phase II/III trials were launched in
December 2012 in Democratic Republic of the Congo
(DRC) followed by Central African Republic and was
completed in November 2017. The oxaborole Scynexis-
7158 (SCYX-7158) entered the phase 1 clinical trials in
March 2012 in Paris, and that was successfully com-
pleted by 2015. These candidates were selected on the
basis of their safety and their potential to treat
advanced-stage sleeping sickness as observed in preclin-
ical studies [34–36].
Methods
Source of parasites
Loa loa mf were obtained from baboons (Papio anubis)
kept in captivity and infected with the human strain of
L. loa according to a modified protocol of Orihel et al.
[12, 13] and Wanji et al. [37]. Briefly, the animals were
splenectomized and infected by subcutaneous injection
of 100 infective larvae (L3) of L. loa from wild-caught
Chrysops flies, with the animals being carefully moni-
tored clinically and parasitologically until patency [38].
Baboons were acquired from hunters in different re-
gions of Cameroon and maintained at a refurbished
monkey house in Kumba. They were fed fruits, fats and
proteins supplemented with vitamins.
Culture constituents and test agents
Complete culture medium (CCM) used to maintain the
parasites in vitro was RPMI 1640 supplemented with 2 g/l
sodium bicarbonate, 25 mM Hepes, 10% fetal bovine
serum (FBS), 100 U penicillin, 100 μg/ml streptomycin
and 2.5 μg/ml amphotericin B. Stock-isotonic Percoll (SIP
- Pharmacia, Uppsala, Sweden) was prepared by mixing 1
part 10× concentrated RPMI 1640 and 9 parts Percoll; di-
lutions were made in RPMI 1640. DMSO, RPMI 1640,
Hepes, sodium bicarbonate, FBS and amphotericin B were
purchased from Sigma Aldrich (St Louis, MO, USA) while
penicillin-streptomycin solutions (Pen-Strep) were ob-
tained from Gibco/Thermo Fisher (Grand Island, NY,
USA). All chemicals were culture grade.
FLBZ and its principal metabolites, reduced flubendazole
(R-FLBZ) and hydrolyzed flubendazole (H-FLBZ), were
obtained from Epichem Pty Ltd, Murdoch University
Campus, South Street, Murdoch WA 6150, Australia. Ima-
tinib was a gift from T. Nutman, NIH, Bethesda, MD,
USA. Ivermectin (IVM), Praziquantel (PZQ), mefloquine
(MFQ), artesunate (ATS), quinine (QN), chloroquine (CQ)
and amodiaquine (AQ) were purchased from Sigma-Al-
drich (St Louis, MO, USA). Fexinidazole and SCYX-7158
were provided by DNDi.
Preparation of parasites
Blood was aseptically collected from infected baboons by
venipuncture into EDTA vacuum tubes. Mf extraction
began immediately upon arrival in the laboratory using a
modified iso-osmotic Percoll extraction method [39, 40].
Discontinuous gradient solutions containing 40%, 50%
and 65% SIP were prepared in 15 ml centrifuge tubes.
An aliquot of 2 ml of undiluted blood was pipetted and
layered gently onto the gradient and the tubes
centrifuged at 900× g for 10 min at 25 °C. The layer con-
taining mf was removed with a syringe and filtered
gently through a 5-μm pore cellulose filter. The filter
was immediately transferred to a Petri dish containing
CCM and incubated at 37 °C for 5 min. After removing
the filter, the remaining fluid containing the mf was cen-
trifuged (300× g for 10 min, 25 °C), the mf quantified
and transferred to culture plates. The quality of mf and
the culture conditions were initially assessed by cultur-
ing the first batch of parasites for 40 days. During this
pre-optimization step, mf retained optimal motility for
at least 10 days, confirming that during the 5 days of
screening, there would be minimal risk of mf dying due
to the stress of the culture conditions. Immediately after
purification, all batches were free of dead parasites, and
the proportion of sluggish mf was usually below 1/100.
Preparation of drug solutions
Stock solutions of each drug were prepared by dissolving
5 mg in 500 μl DMSO in an Eppendorf tube which was
then vortexed. For AQ, CQ and GLV, the DMSO com-
ponent was replaced by double de-ionized water. Follow-
ing this, 20 μl of each suspension was transferred into
10 ml CCM, then two-fold dilutions were made to
obtain final concentrations between 0.156–10 μg/ml. For
the control, 20 μl DMSO was mixed with 10 ml CCM to
make a 0.2% solution. The final concentration of DMSO
was 0.1% in all wells including the negative controls.
Cultures
Parasites were cultured in 48-well plates. Each well con-
tained 200 μl drug solution at the desired concentration
and 200 μl parasite suspension containing 50 ± 5 mf. For
the control wells, 200 μl DMSO (0.2%) in CCM or CCM
only were added to 200 μl parasite suspension containing
approximately 50 mf. Four replicates were tested for each
drug concentration and each experiment was repeated
Njouendou et al. Parasites & Vectors  (2018) 11:223 Page 3 of 11
twice. Motility was assessed under an inverted microscope
at 24 h intervals for 5 days. The mf motility was scored on
a scale of: 0 (immotile), 1 (intermittent shaking of the
head and/or tail region), 2 (sluggish and motile), 3 (highly
active and motile) [41]. On day 5, parasites with no move-
ment were further assessed for viability by measuring the
metabolic reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) to formazan [42].
During this process, mf were incubated for 1 h in a 48-
well plate containing 40 μl/well MTT (0.5 mg/ml) in
phosphate-buffered saline (PBS) and observed under an
inverted microscope for color change in the parasite body
[43]; live parasites stained blue while dead worms were
unstained (Fig. 1).
Data processing
Cultures were evaluated on a relative scale. After scoring
motility daily from day 0 of culture to the last day of
each experiment by counting the number (Ni) of para-
sites with the same score (Si), motility (%) of parasites in
each well at each time point was summarized using the
following formula:
Motility %ð Þ ¼
P
Ni Sið Þ
3P Si  100
Computed motility ranged from 0% if all mf in the
well were immotile (score 0) to 100% when all worms
are actively motile (score 3, the maximum). This formula
was built based on the evaluation of relative score
described for an in vitro screening assay using albenda-
zole, diethylcarbamazine and IVM against Brugia malayi
infective larvae [44]. In the formula, the value 3 repre-
sents the highest score.
Percent reduction in motility for each drug concentration
was calculated on days 3 and 5 using the following formula.
%reduction ¼ Control−drug
Control
 100
The extent of mf mortality was reported as % immotile
(score 0) worms. Raw data were saved on a spreadsheet
in Microsoft Excel 2013, and the motility response
generated. Graphical displays were generated using
GraphPad Prism software. Data were exported to SPSS
version 20 for statistical analysis. Spearman’s rank correl-
ation rho was used to assess the association between the
drug concentration and the reduction in mf motility on
day 5. The effect of drugs on the motility of parasites
was also appreciated by estimating the concentration re-
quired for each drug to reduce the motility of the mf by
50%, defined as CR50. The lower the value of CR50, the
higher the activity of the drug. The CR50 was estimated
using GraphPad Prism software. Results of replicates
were expressed as mean ± standard deviation (SD). The
value of this parameter was used to compare the effects
of the drugs on mf. The effects of drug concentrations
on motility were compared using non-parametric tests.
The Kruskal-Wallis one-way analysis test was used to as-
sess the global significant differences between the me-
dian CR50 of the active drugs and when a difference was
detected, Dunn’s post-hoc test was applied for pairwise
multiple comparisons of the ranked data. This analysis
was performed using the Pairwise Multiple Comparisons
of Mean Rank Sums (PCMR) package in R version 3.1.4.
Drugs were then grouped in ranked categories from the
most active to the inactive. The distribution of median
across drugs in the same rank was compared using ei-
ther Mann-Whitney U-test or Kruskal-Wallis test. Statis-
tical tests were interpreted using a 5% significance level.
Results
Inhibitory effect of the anti-parasitic drugs on the kinetic
of the motility of Loa loa mfs
A total of 13 anti-parasitic drugs were screened against L.
loa mf (Additional file 1: Table S1). The susceptibility of
parasite motility to the drugs over time is shown in Figs.
2 and 3. Generally, mf motility in negative control wells
remained high and close to 100% over the 5 days of culture.
Figure 2 shows the mf motility with incubation time
after treatment with filaricidal, anti-schistosomal and anti-
cancer drugs. In the presence of FLBZ and its two metab-
olites at concentrations between 1.56–10 μg/ml, mf
motility decreased progressively with time. FLBZ (Fig. 2a)
Fig. 1 Photomicrograph (×400) of stained and unstained L. loa
microfilariae after incubation with MTT reagent. This micrograph
shows a live L. loa mf that metabolized MTT into blue formazan
(left arrow) and a dead mf that is unstained (right arrow)
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and its reduced metabolite (Fig. 2b) displayed little activity
against L. loa mf at concentrations ≤ 10 μg/ml. The motil-
ity of mf decreased slightly from the first day after incuba-
tion and fluctuated around 70% within the 5 days. Even at
10 μg/ml, the motility of the parasites remained above
60%. However, the hydrolysed metabolite affected mf mo-
tility from the first day at 10 μg/ml (Fig. 2c), and there was
a decrease in worm motility with time. At 5 and 2.5 μg/
ml, mf motility started to decrease from the third day, and
the extent of reduction was concentration-dependent. At
concentrations < 2.5 μg/ml, mf motility was comparable
to that of negative controls. Although reduction of mf mo-
tility was also observed from day 3 in the presence of 10
μg/ml IVM to 47% on day 5, the motility was still > 70%
at concentrations ≤ 5 μg/ml (Fig. 2d). The anti-
schistosomal PZQ had no effect on the motility of L.
loa mf at 10 μg/ml (Fig. 2e). GLV reduced mf motility
at 10 μg/ml from the first day of incubation to 55% by
day 5 (Fig. 2f ), and the reduction in motility was
concentration-dependent.
The effects of antiprotozoal drugs on mf motility are
illustrated in Fig. 3. The anti-malarial agents MFQ, AQ
and CQ reduced the motility of L. loa mf after 48 h in-
cubation at concentrations > 0.625 μg/ml (Fig. 3a, b and
c, respectively). With AQ and MFQ, the reduction of L.
loa mf motility was concentration-dependent, with MFQ
being more active at higher concentrations. Reductions
in mf motility were obtained with QN and ATS at 5 and
10 μg/ml (Fig. 3d and e, respectively); however; mf ex-
posed to ATS showed no change in motility during the
first 48 h.
SCYX-7158 showed significant (Spearman’s rho =
-0.94285, P = 0.01667) concentration-dependent activ-
ity in reducing L. loa mf motility (Fig. 3f ). At 12.5
μg/ml, which is close to the Cmax values (10 μg/ml)
found in mice after a dose of 25 mg/kg, the reduction
in motility was approximately 50% after 5 days of in-
cubation. Fexinidazole had no significant effect on mf
motility at 10 μg/ml; all worms were actively motile
(Fig. 3g).
a b
c d
e f
Fig. 2 Kinetics of the motility of L. loa microfilariae exposed to different concentrations of anti-filarial, anti-schistosomal and anti-cancer drugs
within 5 days of incubation. a Flubendazole (FLBZ). b Reduced flubendazole (RFLBZ). c Hydrolysed flubendazole (HFLBZ). d Ivermectin (IVM). e
Praziquantel (PZQ). f Imatinib (Gleevec, GLV)
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Relative reduction of mf motility and concentration
reduction 50 (CR50)
A summary of drug effects on mf motility of the mfs with
respect to controls for the 3rd and 5th days in culture is
shown in Table 1, and CR50 values are compared in Fig. 4.
Drugs tested varied in their activity against mf. The relative
reduction of mf motility exposed to MFQ at 10 μg/ml was
100% by day 3. The % reduction of mf motility after 5 days
exposure to FLBZ, R-FLBZ and H-FLBZ at concentrations
of 10 μg/ml was 25.3%, 25.8% and 42.8%, respectively.
Three days post-exposure of mf to these drugs at 10 μg/ml
reduced mf motility by 18.5%, 24.2 and 36.8%, respectively.
The drugs that effected Loa mf in vitro most are MF
and AMQ, while PZQ and fexinidazole displayed no activ-
ity. Based on CR50 values, the drugs tested were ranked in
5 categories in term of their effects (Table 1, Fig. 4). The
first category includes the most active drugs with lowest
CR50 values: MFQ and AM, with CR50 values of 3.9 ± 0.09
and 4.0 ± 0.06 μg/ml, respectively. The second group, with
CR50 values between 8 and 10 μg/ml, includes CQ,
H-FBZ, IVM and ATS, while the third group (12 < mean
CR50 < 14 μg/ml) (if 10 μg/ml was the highest concentra-
tion tested, you cannot have a CR50 value above this) was
the group of QN and GLV. The fourth group included
a b
c d
e
g
f
Fig. 3 Kinetic of the motility of L. loa microfilariae exposed to different concentrations of antiprotozoal drugs within 5 days of incubation. a
Mefloquine (MFQ). b Amodiaquine (AM). c Chloroquine (CQ). d Quinine (QN). e Artesunate (ATS). f SCYX-7158. g Fexinidazole
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drugs with very limited activity at 10 μg/ml (FLBZ and its
reduced metabolite and SCYX-7851). The last group in-
cluded the two inactive drugs, fexinidazole and PZQ, with
undetermined CR50 values.
The Kruskal-Wallis chi-square value was 46.3636 (df =
10, P = 1.232e-06), indicating significant differences in
the activities between various active drugs. Within a
group of drugs with similar activities, differences were
determined using Mann-Whitney U-test and Kruskal-
Wallis test. Although MFQ and AQ were classified in
the same group, MFQ had the significantly (U = 16, P =
0.02857) lowest value of CR50. However, no difference
was found between the drugs within each of the
remaining groups.
Table 1 Relative effects of the agents tested on mf motility at 3 and 5 days of culture at 1.25 and 10 μg/ml (% reduction from controls)
and the CR50 values after 5 days incubation
Ranking Drug Motility reduction
after 3 daysa
Motility reduction
(%) after 5 daysa
Summary statistics for CR50
1.25 μg/ml 10 μg/ml 1.25 μg/ml 10 μg/ml Mean ± SD Median Geometric
mean
Interquartile
range
95% CI
1 (Highly effective) MFQ 1.8 100 9.3 100 3.9 ± 0.1 3.8 3.9 0.16 3.7–4.0
AMQ 2.7 70.6 29.8 95.1 4.1 ± 0.1 4 4.1 0.1 4.0–4.1
2 CQ 3.7 10.3 31.3 63.3 8 ± 0.2 8 8 0.37 7.7–8.3
H-FLBZ 7 36.8 0.9 42.5 8.1 ± 0.7 8.1 8 1.36 6.9–9.3
IVM 2 24.4 5 50.6 8.7 ± 0.5 8.6 8.7 0.83 8.1–9.3
ATS 0.3 5.6 6.5 45.4 9.9 ± 1.4 10.1 9.8 2.58 7.7–12.1
3 QN 0.4 36.4 2.7 36.5 12.7 ± 0.9 12.9 12.7 1.65 11.8–
13.6
GLV 0.5 25.2 1.3 42.1 13.4 ± 2.6 12.8 13.2 4.64 9.3–17.5
4 R-FLBZ 0.6 24.2 10.2 25.8 17.6 ± 3 17.8 17.5 5.56 12.9–
22.4
FLBZ 7.2 18.5 12.9 25.3 21.2 ± 3.2 21.2 21 5.79 16.1–
26.3
SCYX-7851 0.1 18.1 1 31.4 25.4 ± 5.6 24.6 24.9 10.64 20.3–
30.6
5 (Not effective) PZQ 0.2 3.1 2.1 3.5 – – – – –
Fexinidazole 0.4 0.6 1.6 2.6 – – – – –
Abbreviations: CI confidence interval, SD standard deviation, – CR50 values for of PZQ and fexinidazole were not estimated, because they were inactive against L. loa mf
a% reduction relative to the negative control culture
MFQ AQ CQ H−FBZ IVM ATS Imatinib QN R−FBZ FBZ Scynexis
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Fig. 4 Comparative activity of the various drugs against L. loa microfilariae. Box-plots show the activities of the various drugs (CR50) against L. loa microfilariae.
Fexinidazole and PZQ are not represented here because they were inactive. $: P-value for Mann-Whitney U-test. ¥: P-value for Kruskal-Wallis test
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Lethal effect of the anti-parasitic drugs on mf
In addition to reduction in mf motility, lethal effects
(score 0) were observed with some drugs (Fig. 5). This
effect was more pronounced with MFQ than with AQ,
given that at 10 μg/ml, 100% of mf were dead after 24 h
(Fig. 5, Additional file 2: Table S2). Mortality rates for
cultures exposed to MFQ increased with time and drug
concentration. At 5 μg/ml MFQ the rates on day 1 and 5
were 4.5 and 100%, respectively, while for 2.5 μg/ml AQ,
these rates were 2.3 and 85.7%, respectively. No immotile
mf was found in wells containing FLBZ, H-FLBZ, fexini-
dazole, IVM or GLV at 10 μg/ml, the highest concentra-
tion tested, at the 5 day time point. On day 4, SCYX-7158
showed lethal effect on 0.7% of the L. loa mf at 10 μg/ml.
Discussion
Post-treatment SAEs constitute a significant challenge
for mass drug administration programmes in countries
with endemic onchocerciasis and lymphatic filariasis and
co-endemic loiasis. IVM and diethylcarbamazine, the
drugs of choice for these diseases, can induce SAE in
Loa-infected patients [4, 45]. As these SAEs are thought
to be associated with the destruction of huge numbers
of mf by these drugs, a principal aim of scientists and
field program managers is to develop a way of reducing
the circulating number of Loa mf without destroying a
high number at once and thus avoid the SAEs. Develop-
ment of such a drug requires investigation of the activity
of selected candidates on L. loa mf using various experi-
mental models. In this study, we assessed the predictive
value of an in vitro system for the evaluation of drugs
against loiasis.
FLBZ, a promising macrofilaricide candidate [19], was
proposed to be useful in loiasis endemic areas based on
the lack of activity against mf observed in various animal
models [19]. Our results indicate that FLBZ at concen-
trations up to 10 μg/ml reduced the motility of L. loa mf
progressively to a minor degree but did not kill the para-
sites during 5 days of culture. This indicates that the
drug has relatively little direct effect on L. loa mf in
vitro, and may not kill L. loa mf in vivo, as has been
found with other filariae [21, 24]. The same finding was
observed previously with L. loa and B. malayi mf ex-
posed to FLBZ in vitro [25]. In this study, H-FLBZ was
slightly more active against mf than FLBZ or R-FLBZ;
however, it is generally thought that R-FLBZ but not H-
FLBZ is a bioactive anthelmintic, with the latter present
at only very low plasma levels. Our findings support pre-
vious results with other filarial species that showed that
FLBZ had little or no effect on mf [21, 24]. In earlier
studies in humans, no evidence of immediate mf de-
struction was found after i.m. injections of FLBZ [46],
which was supported by a notably slow reduction of the
population of O. volvulus mf over time; likewise, there is
a lack of microfilaricidal activity of this drug on B.
pahangi [21]. FLBZ nevertheless appears to have signifi-
cant effects on adult filariae, and in all likelihood consid-
erably more than IVM does. Thus, its ability to
eliminate adult worms [20–23, 47] without a potentially
dangerous direct effect on mf makes it a good candidate
Fig. 5 Mortality of L. loa microfilariae exposed to different concentrations of the active drugs. Drugs indicated here are those that killed
at least one microfilaria at the concentration indicated
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for use in the global elimination/eradication programs
for filarial infections.
In vitro studies are useful in providing information
concerning the direct effect of drugs against organisms
such as filarial parasites. However, many antiparasitic
drugs require a contribution from the host to be effective,
components that are typically missing from in vitro assays;
this indeed appears to be the case with IVM [15, 16]. It is
important, therefore, to compare in vitro results with
results from in vivo models, and to include both positive
and negative controls in any in vitro study. In this study,
we included a range of chemotherapeutic agents that have
previously been tested against filariae in vitro. Our find-
ings are consistent in general with expectations from
previous in vitro and in vivo work and indicate that our
culture system over a period of five days produces
comparable and valid data. Among the agents used for
comparison here, the anti-malarials ATS, CQ, AQ and QN
have all been found inactive against L. loa mf in humans
[48]. Except CQ, whose in vivo microfilaricidal activity has
been proven against O. volvulus [49], agents that are known
to be active against filariae and that were also active in our
present studies are MQ [25] and imatinib, an anti-cancer
compound recently added to the list of active filaricidal
drugs [17, 18, 50]. PZQ, an anti-schistosomal drug, was also
tested but was inactive in this system.
HAT has considerable public health and economic im-
pacts and is usually fatal when untreated. Current drugs
suffer from poor safety profiles, inadequate regimens,
limited effectiveness, and high cost. In an effort to de-
velop alternative therapies, two new candidates, fexinida-
zole and SCYX-7158, were selected to enter preclinical
studies on the basis of their safety and potential to treat
advanced-stages of sleeping sickness. Most of the foci of
sleeping sickness situated in the forest zones of East and
Central Africa were identified as loiasis endemic areas,
constituting an obstacle to onchocerciasis control and
lymphatic filariasis elimination in sub-Saharan Africa
due to SAEs resulting from massive killing of L. loa mf
by IVM. It is important to determine if similar SAEs are
as threat to the use of these new trypanocides.
Studies on L. loa-trypanosome co-infections have not
been as extended as those on the co-occurrence of L. loa
and Onchocerca spp. The heterogeneous nature of the asso-
ciated clinical manifestations poses problems for prevention
and timely patient management [51]. It is therefore obvious
that any drug discovery strategy for HAT should take into
consideration the issue of SAEs in co-infection with L. loa.
To reduce a risk of SAEs, any drug to be massively used to
control a disease in Loa endemic area, should have little or
no effect on L. loa microfilaria.
Although fexinidazole and SCYX-7158 showed prom-
ising pharmacological activity and safety profiles in pre-
clinical studies, their risk in inducing SAEs is not yet
predicted. The present work thus evaluated fexinidazole
and SCYX-7158 against L. loa mf in vitro. Fexinidazole
had no significant effect on the viability of L. loa mf dur-
ing 5 days of incubation. This highlighted the specificity
of the drug to trypanosomes. In vitro trypanocidal activ-
ity of fexinidazole has already been investigated with
IC50 range (0.2–0.9 μg/ml) against T. brucei species [35].
At a concentration close to 50 times these IC50 values,
the drug had no lethal or paralyzing effect on L. loa mf,
suggesting that fexinidazole is compatible with MDA
programme in Loa endemic areas. However, we cannot
rely only on these data to predict the safety of fexinida-
zole in areas of loaisis endemicity, because it is known
that even though IVM induced SAEs by killing massive
numbers of L. loa mf, it lacks direct microfilaricidal ac-
tivity in vitro [15]. Therefore, it will be interesting to ver-
ify the specific activity of the drug in a murine model of
loiasis and trypanosomiasis co-infection. Although the
murine model of trypanosomiasis is already available,
this is not a case with L. loa mf. However, there is an on-
going effort to develop a mouse model of loiasis.
SCYX-7158 exhibited little activity on L. loa mf. At
concentrations between 12.5–50 μg/ml, this drug inhib-
ited the motility of L. loa mf by more than 50% by day
5. In addition, on days 4 and 5, close to 3% of L. loa mf
were killed. However, these lethal concentrations were
higher than plasma Cmax levels (10 μg/ml) previously
found in mice after a 25 mg/kg dose [36]. As discussed
above, an in vivo system is required to validate the non-
selectivity of this drug, and predict it risk of SAEs in
loiasis co-endemic area.
Conclusions
This study reported, to our knowledge for the first time, the
in vitro microfilaricidal activities of antimalarial drugs MFQ
AQ, CQ, ATS and QN against L. loa mf. These findings
highlight the need to investigate the effect of antimalarial
therapy on loiasis microfilaraemia in the endemic areas.
IVM, GLV, FLBZ and its major metabolites had little effect
on L. loa mf in vitro. PZQ was inactive against L. loa mf in
vitro. Fexinidazole and SCYX-7158 showed no and little ef-
fect, respectively, on L. loa mf viability at concentrations
close to Cmax values. However, further studies need to be
done to confirm these findings in an in vivo model. These
drugs remain candidates for clinical trials for sleeping sick-
ness, even in areas of trypanosomiasis and loiasis co-
endemicity. Given that one cannot rely on in vitro activity
to predict the effects of a drug because of pharmacokinetic
and pharmacodynamic properties that are not incorporated
in culture, it is advised to assess the effect of the above
drugs in an in vivo model of loiasis. The selectivity of the
drug on trypanosomiasis vs loiasis can be assessed in an ex-
perimental model such as the recent development of patent
infections of L. loa in a murine model.
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